What changed in this filing

/stocks — the workspaceLOADING

Item 4. Controls and Procedures

2025-08-14 compared with 2025-05-13 · 14 added, 16 removed, 1 unchanged (97% of the section changed)

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Securities

Exchange Act of 1934, as amended, or the Exchange Act, under the direction of the Chief Executive Officer and the Chief Financial

Officer, we have evaluated our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form

Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls

and procedures are effective as of the end of the period covered by this report.

Our management has concluded that the financial statements

included elsewhere in this Quarterly Report present fairly, in all material respects, our financial position, results of operations and

cash flows in conformity with generally accepted accounting principles.

Changes in Internal Control over Financial

There has not been any change in our internal

control over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange

Act) during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially

affect our internal control over financial reporting.

NeuroOne Medical Technologies

PART II – OTHER INFORMATION

of Disclosure Controls and Procedures

required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, under the direction

of the Chief Executive Officer and the Chief Financial Officer, we have evaluated our disclosure controls and procedures as of the end

of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our Chief Executive Officer and our Chief Financial

Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report.

Our management has concluded that the financial statements included elsewhere in this Quarterly Report present fairly, in all material

respects, our financial position, results of operations and cash flows in conformity with generally accepted accounting principles.

in Internal Control over Financial Reporting

has not been any change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under

the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably

likely to materially affect our internal control over financial reporting.

NeuroOne Medical Technologies Corporation

II – OTHER INFORMATION

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 4. Controls and Procedures